Open Access

High S phase kinase‑associated protein 2 expression is a potential prognostic biomarker for glioma

  • Authors:
    • Zhi‑Jian Cheng
    • Hong‑Qing Cai
    • Min‑Jie Zhang
    • Yi Zhong
    • Jie He
    • Qing Yuan
    • Jia‑Jie Hao
    • Ming‑Rong Wang
    • Jing‑Hai Wan
  • View Affiliations

  • Published online on: July 7, 2020     https://doi.org/10.3892/ol.2020.11818
  • Pages: 2788-2796
  • Copyright: © Cheng et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )
Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )


Abstract

S phase kinase‑associated protein 2 (SKP2), a substrate recognizing protein, serves an important role in promoting cell cycle progression through ubiquitination and degradation of cell cycle inhibitors. In the present study, the clinical significance of SKP2 in gliomas was studied; 395 glioma specimens and 20 non‑neoplastic tissues were collected and immunohistochemical analysis was performed. χ2 test was used to assess the associations between SKP2 expression and clinical parameters. Overall survival (OS) curves were plotted according to the Kaplan‑Meier method. In the tested glioma samples, SKP2 expression was mainly observed in glioblastomas (GBMs). Survival analysis demonstrated that the overall survival time of the high SKP2 expression group was lower compared with the low SKP2 expression group (median OS, 10.04 months vs. 16.50 months; P=0.003). Moreover, SKP2 was independently associated with an unfavorable prognosis in GBMs. In addition, the expression of SKP2 was associated with the expression of phosphorylated retinoblastoma protein and the epidermal growth factor receptor. A combination of SKP2 expression along with isocitrate dehydrogenase 1 (IDH1) mutations and telomerase reverse transcriptase (TERT) promoter mutations was used to classify glioma patients for survival analysis. Patients with low SKP2 expression, IDH1 mutation and wild‑type TERT promoter demonstrated the longest survival time. The findings of the present study, indicate that SKP2 is a potential prognostic biomarker in patients with GBMs.

Related Articles

Journal Cover

September-2020
Volume 20 Issue 3

Print ISSN: 1792-1074
Online ISSN:1792-1082

Sign up for eToc alerts

Recommend to Library

Copy and paste a formatted citation
x
Spandidos Publications style
Cheng ZJ, Cai HQ, Zhang MJ, Zhong Y, He J, Yuan Q, Hao JJ, Wang MR and Wan JH: High S phase kinase‑associated protein 2 expression is a potential prognostic biomarker for glioma. Oncol Lett 20: 2788-2796, 2020
APA
Cheng, Z., Cai, H., Zhang, M., Zhong, Y., He, J., Yuan, Q. ... Wan, J. (2020). High S phase kinase‑associated protein 2 expression is a potential prognostic biomarker for glioma. Oncology Letters, 20, 2788-2796. https://doi.org/10.3892/ol.2020.11818
MLA
Cheng, Z., Cai, H., Zhang, M., Zhong, Y., He, J., Yuan, Q., Hao, J., Wang, M., Wan, J."High S phase kinase‑associated protein 2 expression is a potential prognostic biomarker for glioma". Oncology Letters 20.3 (2020): 2788-2796.
Chicago
Cheng, Z., Cai, H., Zhang, M., Zhong, Y., He, J., Yuan, Q., Hao, J., Wang, M., Wan, J."High S phase kinase‑associated protein 2 expression is a potential prognostic biomarker for glioma". Oncology Letters 20, no. 3 (2020): 2788-2796. https://doi.org/10.3892/ol.2020.11818